-
Metastatic Prostate Cancer Market Research 2025-2035, Featuring Key Players Such as AstraZeneca, Merck, BMS, Daiichi Sankyo, Telix, Exelixis, Eli Lilly and Co, Zenith Epigenetics, MacroGenics - ResearchAndMarkets.com
13 Jun 2025 14:42 GMT
… ; Co., Inc.
Bristol Myers Squibb
Daiichi Sankyo
Telix Pharmaceuticals
Exelixis
Eli Lilly … Portfolio
3.2.3 Top Competitors
3.2.4 Target Customers …
-
Global Antibody Drug Conjugates Market Report 2025-2035, Featuring F. Hoffmann La Roche, Daiichi Sankyo, Seagen, Gilead Sciences, Takeda, Pfizer, Astellas, AstraZeneca, ADC Therapeutics and Immunogen - ResearchAndMarkets.com
21 May 2025 12:40 GMT
… F. Hoffmann La Roche Ltd, Daiichi Sankyo Company, Limited Seagen Inc., Gilead …
F. Hoffmann-La Roche Ltd.
Daiichi Sankyo Company, Limited
Seagen Inc.
Gilead … .3.3 Customer Groups and Competitors
9.3.4 Analyst…
-
Ono’s TGCT therapy wins FDA approval, challenging Daiichi Sankyo
17 Feb 2025 18:19 GMT
… tumour (TGCT), introducing competition to Daiichi Sankyo’s Turalio (pexidartinib).
TGCT is … approval positions it as a competitor to Daiichi Sankyo’s Turalio, which became …
-
Anti-GPC3 Therapies Market Gains Traction with Key Players Advancing Pipeline for Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Gastric Cancer, and Others | DelveInsight
11 Jul 2025 00:14 GMT
… .
Emerging Therapies
9.1.
Key Competitors
9.2.
ECT204: Eureka Therapeutics … , Roche, Shanghai Henlius Biotech, AbbVie, Daiichi Sankyo, Nuvation Bio, PDC*line Pharma …
-
Creative deal structures help life sciences innovators ride out the macro storm
10 Jul 2025 18:15 GMT
… & Co’s partnership with Daiichi Sankyo in 2023 exemplified a multi … manufacturing know-how with a competitor.
Asset purchases coupled with contingent …
-
Bispecifics/BiTE Market Anticipates Impressive Growth Trajectory During the Forecast Period (2025-2034) Across 7MM Due to Their Expansion Beyond Oncology | DelveInsight
08 Jul 2025 22:30 GMT
…
Marketed Drugs
10.1
Key Competitors
10.2
ZIIHERA (zanidatamab): Zymeworks …
Emerging Drugs
11.1
Key Competitors
11.2
CA-170: Aurigene … , Roche, Shanghai Henlius Biotech, AbbVie, Daiichi Sankyo, Nuvation Bio, PDC*line Pharma …
-
Daiichi Sankyo partners Alteogen on subcutaneous Enhertu
08 Nov 2024 15:10 GMT
Daiichi Sankyo has signed a deal worth … $280 million on offer from Daiichi Sankyo if the new formulation of … a major growth product for Daiichi Sankyo and AZ, with sales across … across HER2-positive solid tumours.
Competitors are in the offing, however …
-
Daiichi Sankyo eyes newer cancer drugs to stave off rivals
11 Oct 2024 10:37 GMT
Daiichi Sankyo will seek to maintain its edge over competitors in precision cancer therapies …
-
Four Therapies Hanging On in Troubled TIGIT Space
07 Jul 2025 04:22 GMT
… also leveraging its partnership with Daiichi Sankyo to test combinations of the … get ahead of its cancer competitors with a $200 million spot …
-
Daiichi Sankyo and Merck Enter into Global Development and Commercialization Agreement for MK-6070
07 Aug 2024 01:46 GMT
… Japan where Daiichi Sankyo will maintain exclusive rights. Daiichi Sankyo is solely … manufacturing and supply.
About Daiichi Sankyo
Daiichi Sankyo is an innovative global healthcare … products and patents attained by competitors; challenges inherent in new …
About
© 1995-2025